B-Cell Activating Factor as a Cancer Biomarker and Its
Implications in Cancer-Related Cachexia

J 2015

B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia

ŘIHÁČEK, Michal, Julie BIENERTOVÁ VAŠKŮ, Dalibor VALÍK, Jaroslav ŠTĚRBA, Kateřina PILÁTOVÁ et. al.

Basic information

Original name

B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia

Authors

ŘIHÁČEK, Michal (203 Czech Republic, guarantor), Julie BIENERTOVÁ VAŠKŮ (203 Czech Republic, belonging to the institution), Dalibor VALÍK (203 Czech Republic, belonging to the institution), Jaroslav ŠTĚRBA (203 Czech Republic), Kateřina PILÁTOVÁ (203 Czech Republic, belonging to the institution) and Lenka ZDRAŽILOVÁ DUBSKÁ (203 Czech Republic, belonging to the institution)

Edition

Biomed Research International, New York, HINDAWI PUBLISHING CORPORATION, 2015, 2314-6133

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

Biotechnology and bionics

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.134

RIV identification code

RIV/00216224:14110/15:00083140

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1155/2015/792187

UT WoS

000359550200001

Keywords in English

adipocytokine; B cell activating factor; B cell activating factor receptor; estrogen; immunoglobulin enhancer binding protein; insulin receptor; interferon

Abstract

V originále

B-cell activating factor (BAFF) is a cytokine and adipokine of the TNF ligand superfamily. The main biological function of BAFF in maintaining the maturation of B-cells to plasma cells has recently made it a target of the first FDA-approved selective BAFF antibody, belimumab, for the therapy of systemic lupus erythematosus. Concomitantly, the role of BAFF in cancer has been a subject of research since its discovery. Here we review BAFF as a biomarker of malignant disease activity and prognostic factor in B-cell derived malignancies such as multiple myeloma. Moreover, anti-BAFF therapy seems to be a promising approach in treatment of B-cell derived leukemias/lymphomas. In nonhematologic solid tumors, BAFF may contribute to cancer progression by mechanisms both dependent on and independent of BAFF's proinflammatory role. We also describe ongoing research into the pathophysiological link between BAFF and cancer-related cachexia. BAFF has been shown to contribute to inflammation and insulin resistance which are known to worsen cancer cachexia syndrome. Taking all the above together, BAFF is emerging as a biomarker of several malignancies and a possible hallmark of cancer cachexia.

Links

LM2011017, research and development project

Name: Advanced Cell Immunotherapy Unit - ACIU

Investor: Ministry of Education, Youth and Sports of the CR

Citovat

ŘIHÁČEK, Michal, Julie BIENERTOVÁ VAŠKŮ, Dalibor VALÍK, Jaroslav ŠTĚRBA, Kateřina PILÁTOVÁ and Lenka ZDRAŽILOVÁ DUBSKÁ. B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia. Biomed Research International. New York: HINDAWI PUBLISHING CORPORATION, 2015, vol. 2015, "792187", p. 1-9. ISSN 2314-6133. Available from: https://dx.doi.org/10.1155/2015/792187.

@article{1301076,
   author = {Řiháček, Michal and Bienertová Vašků, Julie and Valík, Dalibor and Štěrba, Jaroslav and Pilátová, Kateřina and Zdražilová Dubská, Lenka},
   article_location = {New York},
   article_number = {"792187"},
   doi = {http://dx.doi.org/10.1155/2015/792187},
   keywords = {adipocytokine; B cell activating factor; B cell activating factor receptor; estrogen; immunoglobulin enhancer binding protein; insulin receptor; interferon},
   language = {eng},
   issn = {2314-6133},
   journal = {Biomed Research International},
   title = {B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia},
   url = {http://downloads.hindawi.com/journals/bmri/aa/792187.pdf},
   volume = {2015},
   year = {2015}
}

TY  - JOUR
ID  - 1301076
AU  - Řiháček, Michal - Bienertová Vašků, Julie - Valík, Dalibor - Štěrba, Jaroslav - Pilátová, Kateřina - Zdražilová Dubská, Lenka
PY  - 2015
TI  - B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia
JF  - Biomed Research International
VL  - 2015
IS  - "792187"
SP  - 1-9
EP  - 1-9
PB  - HINDAWI PUBLISHING CORPORATION
SN  - 23146133
KW  - adipocytokine
KW  - B cell activating factor
KW  - B cell activating factor receptor
KW  - estrogen
KW  - immunoglobulin enhancer binding protein
KW  - insulin receptor
KW  - interferon
UR  - http://downloads.hindawi.com/journals/bmri/aa/792187.pdf
N2  - B-cell activating factor (BAFF) is a cytokine and adipokine of the TNF ligand superfamily. The main biological function of BAFF in maintaining the maturation of B-cells to plasma cells has recently made it a target of the first FDA-approved selective BAFF antibody, belimumab, for the therapy of systemic lupus erythematosus. Concomitantly, the role of BAFF in cancer has been a subject of research since its discovery. Here we review BAFF as a biomarker of malignant disease activity and prognostic factor in B-cell derived malignancies such as multiple myeloma. Moreover, anti-BAFF therapy seems to be a promising approach in treatment of B-cell derived leukemias/lymphomas. In nonhematologic solid tumors, BAFF may contribute to cancer progression by mechanisms both dependent on and independent of BAFF's proinflammatory role. We also describe ongoing research into the pathophysiological link between BAFF and cancer-related cachexia. BAFF has been shown to contribute to inflammation and insulin resistance which are known to worsen cancer cachexia syndrome. Taking all the above together, BAFF is emerging as a biomarker of several malignancies and a possible hallmark of cancer cachexia.
ER  -

ŘIHÁČEK, Michal, Julie BIENERTOVÁ VAŠKŮ, Dalibor VALÍK, Jaroslav ŠTĚRBA, Kateřina PILÁTOVÁ and Lenka ZDRAŽILOVÁ DUBSKÁ. B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia. \textit{Biomed Research International}. New York: HINDAWI PUBLISHING CORPORATION, 2015, vol.~2015, ''792187'', p.~1-9. ISSN~2314-6133. Available from: https://dx.doi.org/10.1155/2015/792187.

Detailed Information on Publication Record